Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company developing antibody-drug conjugates for cancer treatment, has scheduled its Q3 2024 financial results and business updates conference call for November 13, 2024 at 8:00 a.m. Eastern Time. Investors can access the call via domestic (833-255-2826) or international (412-317-0689) dial-in numbers. A webcast will be available on the company's website, with a replay accessible for approximately 90 days following the presentation.
Mersana Therapeutics (NASDAQ: MRSN), un'azienda biofarmaceutica in fase clinica che sviluppa coniugati farmaco-anticorpo per il trattamento del cancro, ha programmato la sua conferenza sui risultati finanziari e aggiornamenti aziendali del Q3 2024 per il 13 novembre 2024 alle 8:00 ora orientale. Gli investitori possono partecipare alla chiamata tramite i numeri di accesso nazionali (833-255-2826) o internazionali (412-317-0689). Sarà disponibile un webcast sul sito web dell'azienda, con una registrazione accessibile per circa 90 giorni dopo la presentazione.
Mersana Therapeutics (NASDAQ: MRSN), una compañía biofarmacéutica en etapa clínica que desarrolla conjugados de anticuerpo-fármaco para el tratamiento del cáncer, ha programado su conferencia sobre resultados financieros y actualizaciones comerciales del Q3 2024 para el 13 de noviembre de 2024 a las 8:00 a.m. hora del Este. Los inversores pueden acceder a la llamada a través de números de marcación nacionales (833-255-2826) o internacionales (412-317-0689). También habrá un webcast disponible en el sitio web de la compañía, con una repetición accesible durante aproximadamente 90 días después de la presentación.
Mersana Therapeutics (NASDAQ: MRSN)는 암 치료를 위한 항체-약물 접합체를 개발하는 임상 단계의 생명공학 회사로서 2024년 3분기 재무 결과 및 사업 업데이트 컨퍼런스 콜을 2024년 11월 13일 오전 8:00 동부 표준시로 예정하였습니다. 투자자들은 국내 전화번호(833-255-2826) 또는 국제 전화번호(412-317-0689)를 통해 통화에 접속할 수 있습니다. 회사 웹사이트에서는 웹캐스트가 제공되며, 발표 후 약 90일 동안 재생이 가능합니다.
Mersana Therapeutics (NASDAQ: MRSN), une société biopharmaceutique en phase clinique développant des conjugués anticorps-médicament pour le traitement du cancer, a programmé sa conférence sur les résultats financiers et les mises à jour commerciales du T3 2024 pour le 13 novembre 2024 à 8h00, heure de l'Est. Les investisseurs peuvent accéder à l'appel via les numéros nationaux (833-255-2826) ou internationaux (412-317-0689). Un webinaire sera disponible sur le site Web de l'entreprise, avec un replay accessible pendant environ 90 jours suivant la présentation.
Mersana Therapeutics (NASDAQ: MRSN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das Antikörper-Wirkstoff-Konjugate zur Krebsbehandlung entwickelt, hat seine Telefonkonferenz zu den finanziellen Ergebnissen und Geschäftsupdates für das Q3 2024 auf den 13. November 2024 um 8:00 Uhr Eastern Time angesetzt. Investoren können über die nationalen (833-255-2826) oder internationalen (412-317-0689) Einwahlnummern an der Konferenz teilnehmen. Ein Webcast wird auf der Unternehmenswebsite verfügbar sein, mit einer Wiederholung, die etwa 90 Tage nach der Präsentation zugänglich ist.
- None.
- None.
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2024 on Wednesday, November 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
When will Mersana Therapeutics (MRSN) report Q3 2024 earnings?
How can investors access Mersana Therapeutics' Q3 2024 earnings call?
How long will Mersana Therapeutics' Q3 2024 earnings webcast be available?
